Portal de Periódicos da CAPES

Synaptic Vesicle Protein 2 (SV2) Isoforms

2012; West Asia Organization for Cancer Prevention; Volume: 13; Issue: 10 Linguagem: Inglês

10.7314/apjcp.2012.13.10.5063

2476-762X

Cindy Bandala, Ángel Miliar-García, César M. Mejía-Barradas, Maricruz Anaya-Ruı́z, Juan Pedro Luna‐Arias, C.I. Bazan-Mendez, Modesto Gómez‐López, Sergio Juárez‐Méndez, Eleazar Lara‐Padilla,

Neurological disorders and treatments

New molecular markers of cancer had emerged with novel applications in cancer prevention and therapeutics, including for breast cancer of unknown causes, which has a high impact on the health of women worldwide. The purpose of this research was to determine protein and mRNA expression of synaptic vesicle 2 (SV2) isoforms A, B and C in breast cancer cell lines. Cultured cell lines MDA-MB-231, SKBR3, T47D were lysed and their protein and mRNA expression analyzed by real-time PCR and western blot technique, respectively. SV2A, B proteins were identified in non-tumor (MCF-10A) and tumor cell lines (MDA-MB-231 and T47D) while SV2C only was found in the T47D cell line. Furthermore, the genomic expression was consistent with protein expression for a such cell line, but in MDA-MB-231 there was no SV2B genomic expression, and the SV2C mRNA and protein were not found in the non tumoral cell line. These findings suggest a possible cellular transdifferentiation to neural character in breast cancer, of possible relevance to cancer development, and point to possible use of SV2 as molecular marker and a vehicle for cancer treatment with botulinum toxin.